Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 6,114 shares of the company's stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $6.79, for a total value of $41,514.06. Following the completion of the sale, the insider now directly owns 5,872,993 shares of the company's stock, valued at $39,877,622.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Morningside Venture Investment also recently made the following trade(s):
Get Kezar Life Sciences alerts:- On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total value of $33,850.00.
- On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.97, for a total value of $84,769.14.
Kezar Life Sciences Stock Down 1.7 %
NASDAQ KZR traded down $0.11 during trading hours on Thursday, reaching $6.25. 366,771 shares of the company's stock were exchanged, compared to its average volume of 720,273. The company's 50-day moving average is $7.10 and its two-hundred day moving average is $8.39. Kezar Life Sciences, Inc. has a one year low of $4.30 and a one year high of $18.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The company has a market capitalization of $427.36 million, a price-to-earnings ratio of -6.28 and a beta of 0.23.
Kezar Life Sciences (NASDAQ:KZR – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. On average, analysts forecast that Kezar Life Sciences, Inc. will post -1.03 EPS for the current fiscal year.Hedge Funds Weigh In On Kezar Life Sciences
Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $26,000. Amalgamated Bank acquired a new position in Kezar Life Sciences during the 1st quarter worth approximately $70,000. Tower Research Capital LLC TRC boosted its position in Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock worth $58,000 after acquiring an additional 3,190 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $68,000. Finally, UBS Asset Management Americas Inc. acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $86,000. Institutional investors and hedge funds own 84.03% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Wells Fargo & Company lowered their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a research note on Tuesday, January 3rd.
Kezar Life Sciences Company Profile
(Get Rating)
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
Featured Articles
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.